Agenus’ (AGEN) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reiterated their buy rating on shares of Agenus (NASDAQ:AGEN) in a report published on Thursday morning,Benzinga reports.

AGEN has been the topic of a number of other research reports. Wall Street Zen lowered Agenus from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 17th. Rodman & Renshaw assumed coverage on Agenus in a research report on Monday, September 28th. They set a “buy” rating and a $19.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $25.00 price objective (down from $30.00) on shares of Agenus in a research report on Tuesday, August 11th. B. Riley Financial restated a “buy” rating and set a $14.00 target price (up from $8.00) on shares of Agenus in a research note on Thursday, July 30th. Finally, Weiss Ratings raised shares of Agenus from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, October 8th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Agenus presently has an average rating of “Moderate Buy” and an average target price of $24.50.

Agenus Trading Down 2.8%

AGEN opened at $6.33 on Thursday. The stock’s 50-day moving average price is $7.68 and its 200 day moving average price is $5.51. Agenus has a 12-month low of $2.71 and a 12-month high of $10.31. The firm has a market cap of $285.86 million, a price-to-earnings ratio of 2.45 and a beta of 1.31.

Agenus (NASDAQ:AGEN) last announced its earnings results on Friday, August 7th. The biotechnology company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.06). The business had revenue of $34.52 million for the quarter, compared to analysts’ expectations of $34.00 million. Agenus had a negative return on equity of 47.68% and a net margin of 69.33%. On average, research analysts forecast that Agenus will post -0.30 earnings per share for the current year.

Institutional Trading of Agenus

Hedge funds and other institutional investors have recently bought and sold shares of the business. Globeflex Capital L P purchased a new stake in Agenus during the 2nd quarter worth about $1,281,000. Bank of America Corp DE increased its holdings in shares of Agenus by 796.7% in the 1st quarter. Bank of America Corp DE now owns 118,782 shares of the biotechnology company’s stock valued at $397,000 after acquiring an additional 105,536 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Agenus in the 2nd quarter valued at about $311,000. Finally, Everhart Financial Group Inc. purchased a new position in shares of Agenus in the 3rd quarter valued at about $100,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.

About Agenus

Agenus Inc is a biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research programs are designed to activate and strengthen the immune system’s ability to recognize and attack tumors, with a focus on therapies that may be used across multiple cancer types.

Agenus develops a range of therapeutic approaches, including immune checkpoint inhibitors, cancer vaccines, bispecific antibodies and other antibody-based treatments. Its pipeline has included investigational therapies targeting immune-regulating pathways, as well as combination regimens intended to improve treatment responses and address resistance to existing cancer therapies.

The company was founded in 1994 as Antigenics and adopted the Agenus name in 2011.